Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POMPAE: Peri-Operative Magnesium Infusion to Prevent Atrial Fibrillation
2022-001393-58Phase 3Terminated
- Sponsor
- HagaZiekenhuis
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of magnesium sulfate in Atrial fibrillation (AFib) (2 arms), sponsored by HagaZiekenhuis. Primary endpoint: Incidence of post-operative atrial fibrillation (POAF) within 7 days. Started Apr 2022; status: terminated.
02
Drugs
magnesium sulfate
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2022-001393-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001393-58.